Literature DB >> 9521329

Human beta-tryptase is a ring-like tetramer with active sites facing a central pore.

P J Pereira1, A Bergner, S Macedo-Ribeiro, R Huber, G Matschiner, H Fritz, C P Sommerhoff, W Bode.   

Abstract

Human tryptase, a mast-cell-specific serine proteinase that may be involved in causing asthma and other allergic and inflammatory disorders, is unique in two respects: it is enzymatically active only as a heparin-stabilized tetramer, and it is resistant to all known endogenous proteinase inhibitors. The 3-A crystal structure of human beta-tryptase in a complex with 4-amidinophenyl pyruvic acid shows four quasi-equivalent monomers arranged in a square flat ring of pseudo 222 symmetry. Each monomer contacts its neighbours at two different interfaces through six loop segments. These loops are located around the active site of beta-tryptase and differ considerably in length and conformation from loops of other trypsin-like proteinases. The four active centres of the tetramer are directed towards an oval central pore, restricting access for macromolecular substrates and enzyme inhibitors. Heparin chains might stabilize the complex by binding to an elongated patch of positively charged residues spanning two adjacent monomers. The nature of this unique tetrameric architecture explains many of tryptase's biochemical properties and provides a basis for the rational design of monofunctional and bifunctional tryptase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521329     DOI: 10.1038/32703

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  66 in total

1.  The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.

Authors:  C P Sommerhoff; W Bode; P J Pereira; M T Stubbs; J Stürzebecher; G P Piechottka; G Matschiner; A Bergner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  New structural motifs on the chymotrypsin fold and their potential roles in complement factor B.

Authors:  H Jing; Y Xu; M Carson; D Moore; K J Macon; J E Volanakis; S V Narayana
Journal:  EMBO J       Date:  2000-01-17       Impact factor: 11.598

3.  Formation of active monomers from tetrameric human beta-tryptase.

Authors:  Ignacio Fajardo; Gunnar Pejler
Journal:  Biochem J       Date:  2003-02-01       Impact factor: 3.857

Review 4.  Protease signalling: the cutting edge.

Authors:  Boris Turk; Dušan Turk; Vito Turk
Journal:  EMBO J       Date:  2012-02-24       Impact factor: 11.598

Review 5.  Approaches for analyzing the roles of mast cells and their proteases in vivo.

Authors:  Stephen J Galli; Mindy Tsai; Thomas Marichal; Elena Tchougounova; Laurent L Reber; Gunnar Pejler
Journal:  Adv Immunol       Date:  2015-02-07       Impact factor: 3.543

6.  The B12 anti-tryptase monoclonal antibody disrupts the tetrameric structure of heparin-stabilized beta-tryptase to form monomers that are inactive at neutral pH and active at acidic pH.

Authors:  Yoshihiro Fukuoka; Lawrence B Schwartz
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

7.  Alternate mRNA splicing in multiple human tryptase genes is predicted to regulate tetramer formation.

Authors:  Nicole E Jackson; Hong-Wei Wang; Katherine J Bryant; H Patrick McNeil; Ahsan Husain; Ke Liu; Nicodemus Tedla; Paul S Thomas; Garry C King; Anusha Hettiaratchi; Jennifer Cairns; John E Hunt
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

8.  Allosteric control of βII-tryptase by a redox active disulfide bond.

Authors:  Kristina M Cook; H Patrick McNeil; Philip J Hogg
Journal:  J Biol Chem       Date:  2013-10-18       Impact factor: 5.157

Review 9.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

10.  Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase.

Authors:  S J Compton; B Renaux; S J Wijesuriya; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.